Related Experiment Video
Updated: Jan 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Attention-guided framework for integrative omics and temporal dynamics in predicting major pathological response in
Xiangfeng Gan1, Jianzhong He2, Wei Zhang3
1Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.
Objective:
This study developed a multiomics model combining radiomics, pathomics, and temporal imaging to predict major pathological response in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherapy.
Methods:
A retrospective, multicenter study was conducted, enrolling 271 patients with stage IB-III NSCLC who received neoadjuvant immunochemotherapy. High-resolution CT images were enhanced using a generative adversarial network-based super-resolution technique. Radiomics features were extracted from multi-sequence CT scans at multiple time points, while pathomics features were derived from whole-slide imaging of surgical specimens. A transformer-based attention mechanism was used to integrate radiomics, pathomics, and temporal imaging data. The model was trained and validated on data from one center and tested on external cohorts. Performance was evaluated using area under the curve (AUC), net reclassification improvement, integrated discrimination improvement, and decision curve analysis.
Results:
The Trans-Model demonstrated superior predictive performance, achieving an AUC of 0.858 (95% CI 0.783 to 0.933) in the external test cohort. It outperformed Rad-Model (AUC: 0.839) and Patho-Model (AUC: 0.753). The Trans-Model effectively stratified patients by survival outcomes, with major pathological response (MPR)-positive patients exhibiting significantly improved 3-year overall survival (87.3% vs 76.1%, p=0.034) and 5-year progression-free survival (45.8% vs 34.7%, p=0.033) compared with MPR-negative patients. Decision curve analysis confirmed the model's clinical utility across a wide range of threshold probabilities.
Conclusion:
The multiomics model, integrating multi-temporal, multi-sequence data with attention-based feature fusion, improves MPR prediction in patients with NSCLC receiving neoadjuvant immunochemotherapy, enabling personalized treatment by identifying responders and optimizing outcomes.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

